This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
Deep diveMEDTECH

CRISPR 3.0 Skin Patch GenePatch Deep Dive: Topical Gene Editing for Genetic Skin Diseases Enters Phase II Clinical Trial

Gene therapy company Dermagenix's CRISPR skin patch GenePatch completes Phase I clinical trial and enters Phase II, delivering CRISPR-Cas12f to epidermal cells via microneedle arrays for topical gene editing treatment of epidermolysis bullosa, with Phase I data showing 85% of patients experienced 3x faster wound healing.

CRISPR 3.0 Skin Patch GenePatch Deep Dive

Gene therapy company Dermagenix announced on August 30 that its CRISPR skin patch GenePatch has successfully completed Phase I safety trials and received FDA approval to proceed to Phase II efficacy trials. This is the world's first clinical-grade product achieving topical gene editing through transdermal delivery.

GenePatch takes the form of a microneedle array patch containing approximately 5,000 soluble microneedles, each 0.5mm long. The microneedles encapsulate lipid nanoparticle-wrapped CRISPR-Cas12f ribonucleoprotein complexes and repair template DNA. After application to the skin, the microneedles penetrate the stratum corneum into the epidermis and dissolve at body temperature to release the gene editing tools.

The first indication is epidermolysis bullosa (EB), a genetic skin disease caused by COL7A1 gene mutations. Patients' skin is extremely fragile, with minor friction causing blisters and wounds. GenePatch's approach is to correct COL7A1 gene mutations in patients' epidermal stem cells, restoring normal type VII collagen synthesis.

The Phase I trial enrolled 32 EB patients primarily for safety evaluation. Results showed GenePatch achieved local gene editing efficiency of approximately 15-20%, sufficient to produce clinically significant improvement in treated areas. 85% of patients reported wound healing speed in treated areas improved by more than 3x, with no serious off-target editing events observed.

"Systemic gene therapy requires injecting editing tools into the bloodstream, facing dual challenges of immune response and off-target risk," said Dermagenix's Chief Science Officer. "Topical transdermal delivery limits editing scope to the epidermal layer, greatly reducing systemic risk."

Phase II plans to enroll 150 EB patients to evaluate efficacy and optimal treatment protocols. Dermagenix expects that if Phase II results are positive, GenePatch could submit for marketing approval as early as end of 2030.